The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study
BackgroundHormonal contraceptive (HC) use has been associated with an increased risk of developing a depressive episode. This might be related to HC’s effect on the serotonergic brain system as suggested by recent cross-sectional data from our group, which show that healthy oral contraceptive (OC) u...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.799675/full |
| _version_ | 1819119962013302784 |
|---|---|
| author | Søren Vinther Larsen Søren Vinther Larsen Brice Ozenne Brice Ozenne Kristin Köhler-Forsberg Kristin Köhler-Forsberg Kristin Köhler-Forsberg Asbjørn Seenithamby Poulsen Vibeke Høyrup Dam Claus Svarer Gitte Moos Knudsen Gitte Moos Knudsen Martin Balslev Jørgensen Vibe Gedso Frokjaer Vibe Gedso Frokjaer Vibe Gedso Frokjaer |
| author_facet | Søren Vinther Larsen Søren Vinther Larsen Brice Ozenne Brice Ozenne Kristin Köhler-Forsberg Kristin Köhler-Forsberg Kristin Köhler-Forsberg Asbjørn Seenithamby Poulsen Vibeke Høyrup Dam Claus Svarer Gitte Moos Knudsen Gitte Moos Knudsen Martin Balslev Jørgensen Vibe Gedso Frokjaer Vibe Gedso Frokjaer Vibe Gedso Frokjaer |
| author_sort | Søren Vinther Larsen |
| collection | DOAJ |
| description | BackgroundHormonal contraceptive (HC) use has been associated with an increased risk of developing a depressive episode. This might be related to HC’s effect on the serotonergic brain system as suggested by recent cross-sectional data from our group, which show that healthy oral contraceptive (OC) users relative to non-users have lower cerebral serotonin 4 receptor (5-HT4R) levels. Here, we determine if cerebral 5-HT4R binding differs between HC non-users, OC users, and hormonal intrauterine device (HIUD) users among women with an untreated depressive episode. Also, we test if antidepressant drug treatment response and its association with pre-treatment 5-HT4R binding depends on HC status.Methods[11C]-SB207145 Positron Emission Tomography imaging data from the NeuroPharm-NP1 Study (NCT02869035) were available from 59 depressed premenopausal women, of which 26 used OCs and 10 used HIUDs. The participants were treated with escitalopram. Treatment response was measured as the relative change in the Hamilton Depression Rating Scale 6 items (rΔHAMD6) from baseline to week eight. Latent variable models were used to evaluate the association between global 5-HT4R binding and OC and HIUD use as well as rΔHAMD6.ResultsWe found no evidence of a difference in global 5-HT4R binding between depressed HC users and non-users (p≥0.51). A significant crossover interaction (p=0.02) was observed between non-users and OC users in the association between baseline global 5-HT4R binding and week eight rΔHAMD6; OC users had 3-4% lower binding compared to non-users for every 10% percent less improvement in HAMD6. Within the groups, we observed a trend towards a positive association in non-users (padj=0.10) and a negative association in OC users (padj=0.07). We found no strong evidence of a difference in treatment response between the groups (p=0.13).ConclusionsWe found no difference in 5-HT4R binding between HC users vs. non-users in depressed women, however, it seemed that 5-HT4R settings differed qualitatively in their relation to antidepressant drug treatment response between OC users and non-users. From this we speculate that depressed OC users constitutes a special serotonin subtype of depression, which might have implications for antidepressant drug treatment response. |
| first_indexed | 2024-12-22T06:13:06Z |
| format | Article |
| id | doaj.art-d2c85266cc914d119155a330d6ba3888 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-22T06:13:06Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-d2c85266cc914d119155a330d6ba38882022-12-21T18:36:11ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-03-011310.3389/fendo.2022.799675799675The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 StudySøren Vinther Larsen0Søren Vinther Larsen1Brice Ozenne2Brice Ozenne3Kristin Köhler-Forsberg4Kristin Köhler-Forsberg5Kristin Köhler-Forsberg6Asbjørn Seenithamby Poulsen7Vibeke Høyrup Dam8Claus Svarer9Gitte Moos Knudsen10Gitte Moos Knudsen11Martin Balslev Jørgensen12Vibe Gedso Frokjaer13Vibe Gedso Frokjaer14Vibe Gedso Frokjaer15Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, DenmarkFaculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkNeurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, DenmarkDepartment of Public Health, Section of Biostatistics, University of Copenhagen, Copenhagen, DenmarkNeurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, DenmarkFaculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkPsychiatric Center Copenhagen, Mental Health Services in the Capital Region of Denmark, Copenhagen, DenmarkNeurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, DenmarkNeurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, DenmarkNeurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, DenmarkNeurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, DenmarkFaculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkPsychiatric Center Copenhagen, Mental Health Services in the Capital Region of Denmark, Copenhagen, DenmarkNeurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, DenmarkFaculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkPsychiatric Center Copenhagen, Mental Health Services in the Capital Region of Denmark, Copenhagen, DenmarkBackgroundHormonal contraceptive (HC) use has been associated with an increased risk of developing a depressive episode. This might be related to HC’s effect on the serotonergic brain system as suggested by recent cross-sectional data from our group, which show that healthy oral contraceptive (OC) users relative to non-users have lower cerebral serotonin 4 receptor (5-HT4R) levels. Here, we determine if cerebral 5-HT4R binding differs between HC non-users, OC users, and hormonal intrauterine device (HIUD) users among women with an untreated depressive episode. Also, we test if antidepressant drug treatment response and its association with pre-treatment 5-HT4R binding depends on HC status.Methods[11C]-SB207145 Positron Emission Tomography imaging data from the NeuroPharm-NP1 Study (NCT02869035) were available from 59 depressed premenopausal women, of which 26 used OCs and 10 used HIUDs. The participants were treated with escitalopram. Treatment response was measured as the relative change in the Hamilton Depression Rating Scale 6 items (rΔHAMD6) from baseline to week eight. Latent variable models were used to evaluate the association between global 5-HT4R binding and OC and HIUD use as well as rΔHAMD6.ResultsWe found no evidence of a difference in global 5-HT4R binding between depressed HC users and non-users (p≥0.51). A significant crossover interaction (p=0.02) was observed between non-users and OC users in the association between baseline global 5-HT4R binding and week eight rΔHAMD6; OC users had 3-4% lower binding compared to non-users for every 10% percent less improvement in HAMD6. Within the groups, we observed a trend towards a positive association in non-users (padj=0.10) and a negative association in OC users (padj=0.07). We found no strong evidence of a difference in treatment response between the groups (p=0.13).ConclusionsWe found no difference in 5-HT4R binding between HC users vs. non-users in depressed women, however, it seemed that 5-HT4R settings differed qualitatively in their relation to antidepressant drug treatment response between OC users and non-users. From this we speculate that depressed OC users constitutes a special serotonin subtype of depression, which might have implications for antidepressant drug treatment response.https://www.frontiersin.org/articles/10.3389/fendo.2022.799675/fullhormonal contraceptionoral contraceptionhormonal intrauterine device[11C]SB207145serotoninmajor depressive disorder |
| spellingShingle | Søren Vinther Larsen Søren Vinther Larsen Brice Ozenne Brice Ozenne Kristin Köhler-Forsberg Kristin Köhler-Forsberg Kristin Köhler-Forsberg Asbjørn Seenithamby Poulsen Vibeke Høyrup Dam Claus Svarer Gitte Moos Knudsen Gitte Moos Knudsen Martin Balslev Jørgensen Vibe Gedso Frokjaer Vibe Gedso Frokjaer Vibe Gedso Frokjaer The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study Frontiers in Endocrinology hormonal contraception oral contraception hormonal intrauterine device [11C]SB207145 serotonin major depressive disorder |
| title | The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study |
| title_full | The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study |
| title_fullStr | The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study |
| title_full_unstemmed | The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study |
| title_short | The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study |
| title_sort | impact of hormonal contraceptive use on serotonergic neurotransmission and antidepressant treatment response results from the neuropharm 1 study |
| topic | hormonal contraception oral contraception hormonal intrauterine device [11C]SB207145 serotonin major depressive disorder |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.799675/full |
| work_keys_str_mv | AT sørenvintherlarsen theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT sørenvintherlarsen theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT briceozenne theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT briceozenne theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT kristinkohlerforsberg theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT kristinkohlerforsberg theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT kristinkohlerforsberg theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT asbjørnseenithambypoulsen theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT vibekehøyrupdam theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT claussvarer theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT gittemoosknudsen theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT gittemoosknudsen theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT martinbalslevjørgensen theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT vibegedsofrokjaer theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT vibegedsofrokjaer theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT vibegedsofrokjaer theimpactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT sørenvintherlarsen impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT sørenvintherlarsen impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT briceozenne impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT briceozenne impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT kristinkohlerforsberg impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT kristinkohlerforsberg impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT kristinkohlerforsberg impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT asbjørnseenithambypoulsen impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT vibekehøyrupdam impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT claussvarer impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT gittemoosknudsen impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT gittemoosknudsen impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT martinbalslevjørgensen impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT vibegedsofrokjaer impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT vibegedsofrokjaer impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study AT vibegedsofrokjaer impactofhormonalcontraceptiveuseonserotonergicneurotransmissionandantidepressanttreatmentresponseresultsfromtheneuropharm1study |